Company: NCNA
Filing Date: 2025-03-20
Form Type: 20-F
Source: 0000950170-25-042709
Chunk: 116

Company: NuCana plc
Filing Date: 2025-03-20
Form: 20-F
Item: Item 4
Chunk 116
---
 and remdesivir, or Veklury®.
 We are led by Hugh Griffith, our founder and Chief Executive Officer, who brings over 30 years of experience in the biopharmaceutical industry, including at Abbott Laboratories (now AbbVie Inc.) and Parke-Davis Warner Lambert (now Pfizer Inc.). Before founding NuCana, he led the operations of Bioenvision, Inc. from start-up through its acquisition by Genzyme Corporation. While at Bioenvision, he was instrumental in developing and commercializing clofarabine, a nucleoside analog for the treatment of pediatric acute leukemia.
 
Our Strategy
 
 Our goal is to improve the survival outcomes and the safety profile of treatment for patients with cancer across a wide range of indications. Our strategy includes the following key components:
•Rapidly develop NUC-7738 as a treatment for patients with solid tumors. 
 
In September 2024, we presented data from the NuTide:701 trial at ESMO on NUC-7738 in combination with pembrolizumab for patients with metastatic melanoma who were refractory to or had relapsed on prior PD-1 inhibitor-based therapy. The data from the Phase 2 part of the NuTide:701 trial showed that 9 of the 12 patients achieved disease control when treated with NUC-7738 in combination with pembrolizumab. Two patients, who had progressed on prior lines of PD-1 inhibitor-based therapy, achieved Partial Responses, one confirmed with a 55% reduction in tumor volume and one unconfirmed with a 32% reduction in tumor volume. These results showed encouraging median PFS of over five months.
 
In 2025, we expect to initiate an expansion of the NuTide:701 trial of NUC-7738 in combination with pembrolizumab in patients with metastatic melanoma and announce data from this NuTide:701 expansion study. We also anticipate obtaining regulatory guidance from the FDA on our registrational strategy for NUC-7738 in melanoma in 2025.
 •Identify additional indications for development of NUC-3373.
 
In order to capitalize on the therapeutic potential of NUC-3373 across other cancer indications and the significant global commercial opportunity for a targeted TS inhibitor, we have initiated a Phase 1b/2 modular clinical trial (NuTide:303) of NUC-3373 in combination with the PD-1 inhibitor pembrolizum